InMode Ltd. (INMD)
INMDNASDAQ-GSBiotechnology: Electromedical & Electrotherapeutic Apparatus
$13.25
+0.0400 (+0.30%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $762.77m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $12.72 to $16.67
- Average volume
- –
- Previous close
- $13.21
Analysts
2 coveringHold0 buy, 2 hold, 0 sell
Targets a year out average $15.00, +13.2% from here
Earnings
Next report
Financials
| Quarter | Mar 2019 |
|---|---|
| Revenue | $30.55m |
| Gross profit | $26.28m |
| Operating income | $9.93m |
| Net income | $10.12m |
News
8 latest- InMode Ltd. Reports Third Quarter 2026 GAAP Revenues of $92.1 MillionFintel · 2 days ago
- InMode Ltd. Special Committee Issues October 26, 2026 Update on Strategic ReviewFintel · Oct 26, 2026
- InMode Receives Unsolicited Bid From Steel Partners RTTNews · Jul 10, 2026
- Doma Perpetual Opposes $16.20/Share Buyout Proposal For InMode RTTNews · Jun 26, 2026
- InMode Appoints Moshik Itzkovich As CFO, Shlomo Nass As Chairman RTTNews · May 20, 2026
- InMode (INMD) Q1 2026 Earnings Call TranscriptThe Motley Fool · May 6, 2026
- InMode (INMD) Q4 2025 Earnings Call TranscriptThe Motley Fool · Feb 10, 2026
- InMode Q4 Preliminary Revenue Rises RTTNews · Jan 8, 2026
The company
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ('RF') technology. InMode strives to enable emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ-GS
- Region
- Middle East
- Website
- inmodemd.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.